Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V) Therapy
Current oncology (Toronto, Ont.)
Bortezomib (Velcade); Venetoclax; chemotherapy refractory; progression without transformation; relapsed/refractory (R/R); splenic marginal zone lymphoma (SMZL)
Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL.
Roche, Kyle C.; DeRosa, Peter A.; Liu, Min-Ling; Nava, Victor E.; and Aggarwal, Anita, "Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V) Therapy" (2022). GW Authored Works. Paper 1153.